Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 8:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 3,667 matching trials from the live ClinicalTrials.gov search.
Conditions
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
Interventions
CD19.CAR-aNKT cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
2
States / cities
Houston, Texas
Conditions
Neuroblastoma
Interventions
Injection of allogeneic neuroblastoma cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cytarabine, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Follicular Lymphoma
Interventions
tisagenlecleucel
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Duarte, California • San Francisco, California • Tampa, Florida + 6 more
Conditions
Multiple Myeloma
Interventions
CC-99712, BMS-986405
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
La Jolla, California • Sarasota, Florida • Buffalo, New York + 4 more
Conditions
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Ibrutinib, Lenalidomide, Rituximab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
22
States / cities
Birmingham, Alabama • Gilbert, Arizona • Los Angeles, California + 18 more
Conditions
Soft Tissue Sarcoma
Interventions
Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Santa Monica, California • Coeur d'Alene, Idaho • Omaha, Nebraska
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Neoplasm
Interventions
Laboratory Biomarker Analysis, Metformin, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphoma
Interventions
Ibrutinib, Carfilzomib, Phone Calls
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
Interventions
Administration of AZD6738
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
La Jolla, California
Conditions
Multiple Myeloma
Interventions
zevor-cel
Biological
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 79 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
12
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
Conditions
Neoplasms
Interventions
JV-394
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Leukemia
Interventions
DTGM fusion protein
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Erdafitinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, FDG-Positron Emission Tomography, Pomalidomide, Teclistamab
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
32
States / cities
Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 23 more
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions
ABT-751, quality-of-life assessment
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 8 more
Conditions
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Laboratory Biomarker Analysis, Ruxolitinib Phosphate
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Ibrutinib, Rituximab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Hodgkin Lymphoma
Interventions
Axatilimab, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Detroit, Michigan • Salt Lake City, Utah
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
imatinib mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Ewing's Sarcoma Family of Tumors
Interventions
CP-751,871
Drug
Lead sponsor
Pfizer
Industry
Eligibility
10 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 6 more
Conditions
Acute Myeloid Leukemia
Interventions
TAS1440, TAS1440 + ATRA
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Tucson, Arizona • Louisville, Kentucky • Ann Arbor, Michigan + 5 more
Conditions
Small Cell Lung Cancer
Interventions
Topotecan and Pasireotide
Drug
Lead sponsor
South Florida Veterans Affairs Foundation for Research and Education
Federal
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Miami, Florida